Information Provided By:
Fly News Breaks for September 29, 2016
VRTX
Sep 29, 2016 | 08:13 EDT
After Vertex lowered its 2016 Orkambi revenue guidance, RBC Capital analyst Michael Yee says that the news "was not a surprise." The analyst remains upbeat on the company's triple CF treatment, and he recommends buying the stock on weakness. He keeps an Outperform rating on the shares.